Saba Nakhle S, Kosseifi Semaan G, Charaf Edris A, Hammad Ahmad N
Division of Hematology/Oncology, Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, James H. Quillen VA Medical Center, TN 37684, USA.
South Med J. 2008 Dec;101(12):1261-2. doi: 10.1097/SMJ.0b013e318188950a.
Newer biological treatment strategies have been developed in the last decade with some promising outcomes. Their safety, however, has been questioned lately with multiple reports of increased risk for malignancies and infectious complications. These reports render their use suboptimal. We report a 44-year-old woman receiving adalimumab (Humira) for advanced juvenile rheumatoid arthritis who then developed acute myelogenic leukemia.
